Acetazolamide Market - Size, Share, Outlook,
and Opportunity Analysis, 2018-2026
Acetazolamide is carbonic anhydrase inhibitor, used in adjuvant treatment of chronic simple
(open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure
glaucoma, epilepsy, edema due to congestive heart failure, drug-induced edema, and acute
mountain sickness in climbers. Acetazolamide promotes acclimatization to altitude, increases
bicarbonate secretion by the kidneys, induces metabolic acidosis, and stimulates ventilation.
Furthermore, according to the BMJ Journal, September 2012, acetazolamide in doses of 250
mg, 500 mg, and 750 mg daily are more effective compared to placebo for preventing acute
mountain sickness. In addition, acetazolamide 250 mg daily is the lowest effective dose to
prevent acute mountain sickness.
Request Sample Copy of Research Report @ https://www.coherentmarketinsights.com/
insight/request-sample/2396
The global acetazolamide market size was valued at US$ 183.2 Mn in 2017, and is expected to
witness a CAGR of 4.8% during the forecast period (2018 – 2026).
Market Dynamics
Increasing prevalence of glaucoma and its risk factors among global population is propelling
demand for acetazolamide during the forecast period. Moreover, acetazolamide is commonly
used for preventing high altitude illness, this increases the utility of the drug.
For instance, according to the International Journal of Advanced Medical and Health Research,
2015, glaucoma is seen to be the second major reason causing blindness among people across
the world, followed by cataract.
Furthermore, according to the BrightFocus Foundation, June 2017 data findings, over 3 million
Americans suffer from glaucoma, out of which 2.7 million (aged 40 and older) are affected by
its most common form, open-angle glaucoma. Also, high prevalence of eye disorder in the
geriatric population and nutritional deficiency in the younger population due to changing food
habits are other factors affecting the health of the people globally, which might lead to boost